TAYD - テイラ―・デバイス （Taylor Devices Inc.）

Taylor Devices specializes in shock-absorbing devices for construction and aerospace uses, among others. See here for the business and TAYD stock outlook.

Taylor Devices is a well-established company with a high level of expertise in the shock and vibration control field. See why we are a hold on TAYD stock.

Taylor Devices press release (NASDAQ:TAYD): Q2 GAAP EPS of $0.45.Revenue of $10.5M (+35.5% Y/Y).

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH ) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ: QTNT ) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Baudax Bio, Inc. (NASDAQ: BXRX ) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. Palisade Bio, Inc. (NASDAQ: PALI ) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction in intra-abdominal adhesions in subjects following elective bowel resection. Nuwellis, Inc. (NASDAQ: NUWE ) shares climbed 40.5% to $12.88. Nuwellis announced an exclusive U.S. license and distribution agreement for SeaStar Medical Holding’s Selective Cytopheretic Device (SCD) for acute kidney injury (AKI) in children.

Gainers:Expion360 Inc. (XPON) +24%.Taylor Devices, Inc

Taylor Devices is a well-established company with a high level of expertise in the shock and vibration control field. See why we are a hold on TAYD stock.

Taylor Devices press release (NASDAQ:TAYD): Q2 GAAP EPS of $0.45.Revenue of $10.5M (+35.5% Y/Y).

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH ) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ: QTNT ) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Baudax Bio, Inc. (NASDAQ: BXRX ) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. Palisade Bio, Inc. (NASDAQ: PALI ) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction in intra-abdominal adhesions in subjects following elective bowel resection. Nuwellis, Inc. (NASDAQ: NUWE ) shares climbed 40.5% to $12.88. Nuwellis announced an exclusive U.S. license and distribution agreement for SeaStar Medical Holding’s Selective Cytopheretic Device (SCD) for acute kidney injury (AKI) in children.

Gainers:Expion360 Inc. (XPON) +24%.Taylor Devices, Inc

Taylor Devices Inc (NASDAQ: TAYD ) reported second-quarter FY23 sales growth of 35% year-on-year, to $10.49 million. Net earnings for Q2 totaled $1.6 million versus $0.7 million … Full story available on Benzinga.com

Taylor Devices press release (NASDAQ:TAYD): Q2 GAAP EPS of $0.45.Revenue of $10.5M (+35.5% Y/Y).

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH ) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ: QTNT ) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Baudax Bio, Inc. (NASDAQ: BXRX ) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. Palisade Bio, Inc. (NASDAQ: PALI ) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction in intra-abdominal adhesions in subjects following elective bowel resection. Nuwellis, Inc. (NASDAQ: NUWE ) shares climbed 40.5% to $12.88. Nuwellis announced an exclusive U.S. license and distribution agreement for SeaStar Medical Holding’s Selective Cytopheretic Device (SCD) for acute kidney injury (AKI) in children.

Gainers:Expion360 Inc. (XPON) +24%.Taylor Devices, Inc

Taylor Devices Inc (NASDAQ: TAYD ) reported second-quarter FY23 sales growth of 35% year-on-year, to $10.49 million. Net earnings for Q2 totaled $1.6 million versus $0.7 million … Full story available on Benzinga.com

NORTH TONAWANDA, N.Y. , Dec. 29, 2022 /PRNewswire/ -- Taylor Devices, Inc. (NASDAQ SmallCap: "TAYD") announced today that it had 2 nd quarter sales of $10,497,366 , up 35% from last year''s 2 nd quarter sales of $7,757,986 while sales for the 1 st six months were $19,588,065 , up 30% from last year''s 1 st six-month sales of $15,065,723 . Net earnings for the 2 nd quarter were $1,559,508 , up significantly from last year''s 2 nd quarter net earnings of $659,804 with net earnings for the 1 st six months finishing at $2,561,879 , also up significantly from last year''s net earnings for the 1 st six months of $841,681 . "Our FY23 2nd quarter and 1st half sales finished significantly better than last year''s levels respectively with all three of our customer product groups; Aerospace/Defense, Structural and Industrial, sales levels improved year-on-year," stated Tim Sopko , CEO. He continued, "This also sets a new high record for sales in the first six months of a fiscal year concurrent with sales in the quarter exceeding the $9 million threshold for the 3 rd consecutive quarter, another first for our company." He further commented, "Earnings for the 2 nd quarter and 1 st half are also significantly improved over last year''s levels both in total dollars as well as a percentage of sales; 136% better for the quarter and 204% better for the 1 st half." He continued, "This profitable growth is largely due to our team''s disciplined adherence to our growth strategies as well as their excellent work on continuous improvements …